Hypertension, or high blood pressure, is a serious health concern, but a recent study on a new hypertension polypill has shown promising results . The polypill, called GMRx2, combines three anti-hypertensive drugs in low doses into a single pill. In the study, 81% of participants who took GMRx2 achieved blood pressure control after just one month, compared to 55% of those who received standard care. This improvement was sustained at six months, with 82% of participants achieving blood pressure control. The study's results are significant, as they suggest that this new polypill could be a game-changer in reducing rates of cardiovascular disease, particularly in countries with the highest burden .
Hypertension, or high blood pressure, is a serious health concern, but a recent study on a new hypertension polypill has shown promising results . The polypill, called GMRx2, combines three anti-hypertensive drugs in low doses into a single pill. In the study, 81% of participants who took GMRx2 achieved blood pressure control after just one month, compared to 55% of those who received standard care. This improvement was sustained at six months, with 82% of participants achieving blood pressure control. The study's results are significant, as they suggest that this new polypill could be a game-changer in reducing rates of cardiovascular disease, particularly in countries with the highest burden .
